University of Florida Research Foundation, Incorporated

H. Lee Moffitt Cancer Center and Research Institute, Inc.

University of South Florida

Daniel M Sullivan

David A Ostrov

Thomas Cardon Rowe

Joel G Turner

Richard Jove

Gerold Bepler

Eric Bruce Haura

Susan E Minton

Carlos A Muro-Cacho

Topoisomerase II alpha (topo II&#x3b1;) is exported from the cell nucleus in human myeloma cells by a chromosome-maintenance protein-1 (CRM1)-dependent mechanism, resulting in topo II inhibitor resistance. The nuclear export signal (NES) of topo II&#x3b1; is unique, making it a potential target for small molecule inhibitors. Small molecules NES inhibitors were identified, which inhibited binding of topo II&#x3b1; to the export receptor CRM1. Inhibition was specific to topo II&#x3b1; as p53 trafficking was unaffected along with topo II&#x3b1; protein expression and function (decatenation). These topo II&#x3b1;-specific nuclear export inhibitors may potentially lead to a new approach in circumventing drug resistance in multiple myeloma. The compounds provide a protocol for treating multiple myeloma or an oncogenic disease. Further, the topoisomerase II nuclear export signal inhibitor may be combined with a topoisomerase II inhibitor.

Drug targets to overcome de novo drug-resistance in multiple myeloma

A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase II&#x3b1; and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo II&#x3b1; have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.

Nuclear export inhibitors of topoisomerase II alpha

Methods are provided for predicting responsiveness of cancer cells to chemotherapy by measuring the level of phosphorylated Stat or the level of expression of Survivin in a cancer and comparing the level in the cancer cell to the respective level in a control. Also provided are methods of selecting a chemotherapeutic treatment for a subject diagnosed with cancer by measuring the level of phosphorylated Stat or the level of expression of Survivin in a cancer and comparing the level in the cancer cell to the respective level in a control. Kits for performing the methods are also provided. Methods for modulating Survivin-dependent apoptosis in a cancer cell are also disclosed.

Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments

Growing community of inventors

Lutz, FL, United States of America

Daniel M Sullivan